231 related articles for article (PubMed ID: 9454747)
41. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
[TBL] [Abstract][Full Text] [Related]
42. Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
Nevel KS; Pentsova E; Daras M
Leuk Lymphoma; 2019 Jul; 60(7):1677-1684. PubMed ID: 30648449
[TBL] [Abstract][Full Text] [Related]
43. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
[TBL] [Abstract][Full Text] [Related]
44. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
45. Central nervous system-directed preventative therapy in adults with lymphoma.
McMillan A
Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
[TBL] [Abstract][Full Text] [Related]
46. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Boehme V; Schmitz N; Zeynalova S; Loeffler M; Pfreundschuh M
Blood; 2009 Apr; 113(17):3896-902. PubMed ID: 19144985
[TBL] [Abstract][Full Text] [Related]
47. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
Dargenio M; Bonifacio M; Chiaretti S; Vitale A; Fracchiolla NS; Papayannidis C; Giglio F; Salutari P; Audisio E; Scappini B; Zappasodi P; Defina M; Forghieri F; Scattolin AM; Todisco E; Lunghi M; Guolo F; Del Principe MI; Annunziata M; Lazzarotto D; Cedrone M; Pasciolla C; Imovilli A; Tanasi I; Trappolini S; Cerrano M; La Starza R; Krampera M; Di Renzo N; Candoni A; Pizzolo G; Ferrara F; Foà R
Br J Haematol; 2023 Feb; 200(4):440-450. PubMed ID: 36335916
[TBL] [Abstract][Full Text] [Related]
48. [Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system].
Paulus JA; Bos GM; Löwenberg B; Van Den Bent MJ
Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2196-200. PubMed ID: 9864481
[TBL] [Abstract][Full Text] [Related]
49. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
50. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.
Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH
J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958
[TBL] [Abstract][Full Text] [Related]
51. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Korfel A; Thiel E
Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
[TBL] [Abstract][Full Text] [Related]
52. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
53. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
Bashir RM; Bierman PJ; Vose JM; Weisenburger DD; Armitage JO
Am J Clin Oncol; 1991 Dec; 14(6):478-82. PubMed ID: 1720278
[TBL] [Abstract][Full Text] [Related]
54. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.
Yi JH; Kim JH; Baek KK; Lim T; Lee DJ; Ahn YC; Kim K; Kim SJ; Ko YH; Kim WS
Ann Oncol; 2011 Jul; 22(7):1636-1643. PubMed ID: 21220520
[TBL] [Abstract][Full Text] [Related]
55. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
56. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
Reman O; Pigneux A; Huguet F; Vey N; Delannoy A; Fegueux N; de Botton S; Stamatoullas A; Tournilhac O; Buzyn A; Charrin C; Boucheix C; Gabert J; Lhéritier V; Vernant JP; Fière D; Dombret H; Thomas X;
Leuk Res; 2008 Nov; 32(11):1741-50. PubMed ID: 18508120
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
[TBL] [Abstract][Full Text] [Related]
58. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
59. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL).
Chihara D; Asano N; Ohmachi K; Nishikori M; Okamoto M; Sawa M; Sakai R; Okoshi Y; Tsukamoto N; Yakushijin Y; Nakamura S; Kinoshita T; Ogura M; Suzuki R
Ann Oncol; 2015 May; 26(5):966-973. PubMed ID: 25712457
[TBL] [Abstract][Full Text] [Related]
60. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
